The Configuration of Biomolecular Markers in Cancer of the Uterine Cervix. Personalized Therapy. Monitoring and PrognosisV.M. Prunoiu, M.A. Marincaş, C. Cirimbei, S. Ionescu, S. Zurac, M. Radu, R. Nicolaescu, E. Brătucu, N.D. Straja
Original article, no. 2, 2015
Introduction: The paper deals with the diagnosis of someaggressive forms of uterine cervix cancers, resistant to radio chemotherapy, usingbiomolecular markers.For this study, thedestruction of tumours in stages II-IIIBis carried out by hyperthermiainduced by different sources of energy. The aimed targetsaretoembed a quick and simple technique of haemostasisused in bleeding uterine cervix tumours associated with acuteanaemiain the treatment protocols and to identifybiomolecularcriteria revealing tumour aggressiveness and treatment response.Method: The proposed method consists in radiofrequencyablation (RFA) applied touterine cervix bleeding tumours withacute secondary anaemia. Studying 16 patients displayingaggressive cancer forms resistant to radio chemotherapytreated by the abovementioned method, we assessed that thecommonly present markers: Ki67, p53 and Bcl-2, may be asubstantial indication of such cases. Aggressiveness and treatment resistance was defined based on clinical and paraclinicalinvestigations.Results: RFA haemostasis achieved in approximately 20 minproved the efficiency of this method. A secondary importanteffect was local tumour volume decrease, resulting in theimprovement of radio-chemotherapy responsiveness.Conclusions: Once an aggressive and radio-chemotherapyresistant cancer is diagnosed,thequantitative, qualitative andassociative presence of the biomolecular markers mentionedhereinbefore, could influence the personalised treatmentattitude (radiofrequency, neoadjuvant chemotherapy), which onthe long term, may increase patient survival and life qualityimprovement.